Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Non-Current Assets (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Non-Current Assets for 3 consecutive years, with $23.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 62.15% to $23.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $88.3 million, a 162.26% increase, with the full-year FY2025 number at $23.3 million, up 62.15% from a year prior.
  • Non-Current Assets was $23.3 million for Q4 2025 at Nuvation Bio, down from $24.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $24.0 million in Q3 2025 to a low of $4.2 million in Q2 2023.
  • A 3-year average of $11.8 million and a median of $7.1 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: grew 12.79% in 2024, then skyrocketed 264.44% in 2025.
  • Nuvation Bio's Non-Current Assets stood at $5.0 million in 2023, then skyrocketed by 184.57% to $14.4 million in 2024, then surged by 62.15% to $23.3 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Non-Current Assets are $23.3 million (Q4 2025), $24.0 million (Q3 2025), and $24.0 million (Q2 2025).